Results from a Phase 1b Study of UCB0599, an orally available, brain-penetrant inhibitor of alphasynuclein (ASYN) Misfolding in people living with parkinson's disease (PD)

Authors
Category Primary study
JournalNeurology
Year 2021
This article has no abstract
Epistemonikos ID: 5c88056f7e89f4ade1f61a857eb85a773f69e0ce
First added on: Feb 13, 2025